Related Experiment Video

Updated: May 17, 2026

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
09:56

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice

Published on: February 14, 2021

Shortening baroreflex delay in hypertrophic cardiomyopathy patients -- an unknown effect of β-blockers

Agnieszka Katarzynska-Szymanska1, Romuald Ochotny, Zofia Oko-Sarnowska

  • 1Department of Cardiology - First Department, Poznan University of Medical Sciences, Poznan, Poland.

British Journal of Clinical Pharmacology
|November 7, 2012
PubMed

Insights

Hypertrophic cardiomyopathy patients not on beta-blockers show prolonged baroreflex delay. Beta-blocker treatment normalizes this delay, indicating improved autonomic control in hypertrophic cardiomyopathy.

Area of Science:

  • Cardiology
  • Autonomic Neuroscience
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) involves left ventricular hypertrophy and impaired cardiac function.
  • Abnormal autonomic balance may contribute to HCM progression.
  • Beta-blockers are standard HCM treatment, affecting autonomic function.

Purpose of the Study:

  • To assess autonomic cardiovascular control in HCM patients.
  • To investigate the impact of beta-blockers on autonomic function in HCM.
  • To compare autonomic regulation in treated, untreated HCM patients, and healthy controls.

Main Methods:

  • Studied 51 HCM outpatients (treated/untreated) and 14 healthy controls.
  • Measured continuous non-invasive blood pressure.
  • Assessed heart rate variability and spontaneous baroreflex function.

Main Results:

  • Heart rate variability and baroreflex sensitivity were similar across groups.
  • Baroreflex delay was significantly longer in untreated HCM patients.
  • Beta-blocker treatment normalized baroreflex delay compared to controls.

Conclusions:

  • Untreated hypertrophic cardiomyopathy is associated with prolonged baroreflex delay.
  • Beta-blocker therapy normalizes this baroreflex delay in HCM patients.
  • Beta-blockers may improve autonomic cardiovascular regulation in HCM.
Abstract

More Related Videos

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...